"label","uuid:ID","instanceType","rationale","id","description","name"
"","109bfe68-e5ab-424a-b5e5-9d8d1abcca7a","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","The main design for the study","Study Design 1"
